VP4 Is a Determinant of Alpha-Defensin Modulation of Rotaviral Infection.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
13 04 2022
Historique:
pubmed: 15 3 2022
medline: 16 4 2022
entrez: 14 3 2022
Statut: ppublish

Résumé

Fecal-oral pathogens encounter constitutively expressed enteric alpha-defensins in the intestine during replication and transmission. Alpha-defensins can be potently antiviral and antibacterial; however, their primary sequences, the number of isoforms, and their activity against specific microorganisms often vary greatly between species, reflecting adaptation to species-specific pathogens. Therefore, alpha-defensins might influence not only microbial evolution and tissue tropism within a host but also species tropism and zoonotic potential. To investigate these concepts, we generated a panel of enteric and myeloid alpha-defensins from humans, rhesus macaques, and mice and tested their activity against group A rotaviruses, an important enteric viral pathogen of humans and animals. Rotaviral adaptation to the rhesus macaque correlated with resistance to rhesus enteric, but not myeloid, alpha-defensins and sensitivity to human alpha-defensins. While mouse rotaviral infection was increased in the presence of mouse enteric alpha-defensins, two prominent genotypes of human rotaviruses were differentially sensitive to human enteric alpha-defensins. Furthermore, the effects of cross-species alpha-defensins on human and mouse rotaviruses did not follow an obvious pattern. Thus, exposure to alpha-defensins may have shaped the evolution of some, but not all, rotaviruses. We then used a genetic approach to identify the viral attachment and penetration protein, VP4, as a determinant of alpha-defensin sensitivity. Our results provide a foundation for future studies of the VP4-dependent mechanism of defensin neutralization, highlight the species-specific activities of alpha-defensins, and focus future efforts on a broader range of rotaviruses that differ in VP4 to uncover the potential for enteric alpha-defensins to influence species tropism.

Identifiants

pubmed: 35285683
doi: 10.1128/jvi.02053-21
pmc: PMC9006894
doi:

Substances chimiques

Viral Structural Proteins 0
alpha-Defensins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0205321

Subventions

Organisme : NIAID NIH HHS
ID : T32 AI083203
Pays : United States
Organisme : NIH HHS
ID : P51 OD010425
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI104920
Pays : United States
Organisme : NIAID NIH HHS
ID : F30 AI140620
Pays : United States
Organisme : NIH HHS
ID : S10 OD026741
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000423
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI125249
Pays : United States

Références

Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
PLoS Pathog. 2016 Mar 02;12(3):e1005474
pubmed: 26933888
J Virol. 2010 Apr;84(8):4041-9
pubmed: 20130047
Nat Rev Dis Primers. 2017 Nov 09;3:17083
pubmed: 29119972
Virology. 1994 Nov 1;204(2):642-50
pubmed: 7941332
J Virol. 2018 Nov 27;92(24):
pubmed: 30258012
J Virol. 2004 Nov;78(21):11622-31
pubmed: 15479803
S Afr Med J. 1963 Apr 20;37:407-11
pubmed: 13932505
J Biol Chem. 2012 Jul 13;287(29):24554-62
pubmed: 22637473
JAMA Pediatr. 2018 Oct 1;172(10):958-965
pubmed: 30105384
Vet Microbiol. 2010 Jan 27;140(3-4):246-55
pubmed: 19781872
Mol Immunol. 2003 Nov;40(7):469-75
pubmed: 14568394
PLoS Pathog. 2010 Jun 24;6(6):e1000959
pubmed: 20585634
Curr Opin Virol. 2021 Jun;48:42-48
pubmed: 33887683
PLoS Pathog. 2020 Nov 24;16(11):e1009018
pubmed: 33232373
Pediatr Res. 2016 Aug;80(2):306-10
pubmed: 27049291
J Virol. 1993 May;67(5):2448-55
pubmed: 8386262
J Biol Chem. 2008 Dec 19;283(51):35869-77
pubmed: 18930922
Curr Med Chem. 2020;27(9):1420-1443
pubmed: 31385762
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18129-34
pubmed: 16330776
Lancet Infect Dis. 2014 Sep;14(9):847-56
pubmed: 25082561
Semin Immunol. 2013 Nov 30;25(5):334-41
pubmed: 24239045
J Am Chem Soc. 2003 Mar 5;125(9):2402-3
pubmed: 12603122
PLoS Pathog. 2017 Jun 16;13(6):e1006446
pubmed: 28622386
Mol Biol Evol. 2010 Oct;27(10):2333-43
pubmed: 20457584
Science. 2009 Jun 12;324(5933):1444-7
pubmed: 19520960
Cell Host Microbe. 2008 Jan 17;3(1):11-9
pubmed: 18191790
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Hum Vaccin Immunother. 2019;15(12):3003-3008
pubmed: 31124743
J Infect Dis. 2010 Sep 15;202(6):971-8
pubmed: 20695797
J Mol Biol. 2013 Dec 13;425(24):4965-80
pubmed: 24095897
J Virol. 2018 Apr 13;92(9):
pubmed: 29467318
Mol Biol Evol. 2017 Jul 1;34(7):1812-1819
pubmed: 28387841
Annu Rev Virol. 2017 Sep 29;4(1):369-391
pubmed: 28715972
Cell Mol Gastroenterol Hepatol. 2016 Mar 12;2(3):263-273
pubmed: 28090561
Front Immunol. 2020 May 07;11:764
pubmed: 32457744
Infect Immun. 1999 Nov;67(11):6139-44
pubmed: 10531277
PLoS Pathog. 2014 Sep 04;10(9):e1004360
pubmed: 25188351
Nat Immunol. 2005 Jun;6(6):551-7
pubmed: 15908936
J Virol. 2013 Aug;87(15):8307-16
pubmed: 23698306
Pathog Immun. 2019 Sep 12;4(2):196-234
pubmed: 31583330
PLoS Pathog. 2019 Dec 16;15(12):e1008180
pubmed: 31841560
J Pept Res. 2004 Sep;64(3):118-25
pubmed: 15317502
Euro Surveill. 2016;21(2):
pubmed: 26794258
J Virol. 2014 Jan;88(2):948-60
pubmed: 24198413
Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2349-2354
pubmed: 28137864
J Virol. 1986 Dec;60(3):1068-74
pubmed: 3023659
Nat Immunol. 2002 Jun;3(6):583-90
pubmed: 12021776
Curr Opin Virol. 2018 Dec;33:106-112
pubmed: 30145433
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1516-21
pubmed: 16432216
mBio. 2017 Jan 24;8(1):
pubmed: 28119475
Immunol Rev. 2012 Jan;245(1):84-112
pubmed: 22168415
Infect Immun. 2011 Jan;79(1):459-73
pubmed: 21041494
J Virol. 2015 Mar;89(5):2866-74
pubmed: 25540379
Nature. 2021 Feb;590(7847):666-670
pubmed: 33442061
Infect Immun. 2004 Mar;72(3):1470-8
pubmed: 14977952
Protein Sci. 1995 Nov;4(11):2411-23
pubmed: 8563639
Comput Appl Biosci. 1992 Jun;8(3):275-82
pubmed: 1633570

Auteurs

Ciara T Hu (CT)

Department of Microbiology, University of Washington School of Medicinegrid.471394.c, Seattle, Washington, USA.

Karina Diaz (K)

Department of Microbiology, University of Washington School of Medicinegrid.471394.c, Seattle, Washington, USA.

Linda C Yang (LC)

Department of Microbiology, University of Washington School of Medicinegrid.471394.c, Seattle, Washington, USA.

Anjali Sharma (A)

Department of Microbiology, University of Washington School of Medicinegrid.471394.c, Seattle, Washington, USA.

Harry B Greenberg (HB)

Department of Medicine and Department of Microbiology and Immunology, Stanford School of Medicine, Stanford, California, USA.

Jason G Smith (JG)

Department of Microbiology, University of Washington School of Medicinegrid.471394.c, Seattle, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH